Business
Income Tax Act 2025 Gets President’s Assent: Centre Notifies New Rules To Replace 1961 Law
Last Updated:
The new Act removes redundant provisions and archaic language and cuts the number of Sections from 819 in the Income Tax Act, 1961, to 536 and the number of chapters from 47 to 23.
Income Tax Act, 2025.
The central government on Friday notified the Income Tax Act, 2025, in the Official Gazette. It comes a day after the President gave assent to the Act on Thursday. The Act, which will come into effect from April 1, 2026, consolidates and amends the existing Income Tax Act, 1961.
“The Income-tax Act, 2025 has received the Hon’ble President’s assent on 21st Aug 2025. A landmark reform replacing the 1961 Act, it ushers in a simpler, transparent & compliance-friendly direct tax regime. Access the official document here: https://egazette.gov.in/(S(p0hzyo3qrxli3juyloktgdrv))/ViewPDF.aspx,” Income Tax India said in a post on X on August 22.
The Act was passed by Parliament in the just-concluded monsoon session.
The Income-tax Act, 2025 has received the Hon’ble President’s assent on 21st Aug 2025.A landmark reform replacing the 1961 Act, it ushers in a simpler, transparent & compliance-friendly direct tax regime.
Access the official document here: https://t.co/wOPk1PFQbP pic.twitter.com/Xw84hzpPb3
— Income Tax India (@IncomeTaxIndia) August 22, 2025
The new Act removes redundant provisions and archaic language and reduces the number of Sections from 819 in the Income Tax Act of 1961 to 536 and the number of chapters from 47 to 23. The number of words had been reduced from 5.12 lakh to 2.6 lakh in the new Income Tax Bill, and for the first time, it introduces 39 new tables and 40 new formulas, replacing the dense text of the 1961 law to enhance clarity.
As the new law will come into force from April 1, 2026, the computer systems of the Income Tax department are required to be rebooted to operationalise the new legislation.
The new Income Tax Bill was drafted within a record time of six months and introduced in the Budget session in February 2025. It was referred to the Select Committee for a comprehensive study of the Bill. Subsequently, in order to incorporate the suggestions made by the Committee, the Bill (No.1) was withdrawn and a fresh Bill (No.2) was introduced in the monsoon session of Parliament.
While presenting the revised Bill in Lok Sabha on August 11, Finance Minister Nirmala Sitharaman said the government had accepted “almost all of the recommendations of the Select Committee”, along with suggestions from stakeholders to ensure the law’s intent is “conveyed more accurately”.
“There are corrections in the nature of drafting, alignment of phrases, consequential changes and cross-referencing. Therefore, a decision has been taken by the government to withdraw the Income Tax Bill, 2025, as reported by the Select Committee. Consequently, Income-tax (No. 2) Bill, 2025, has been prepared to replace the Income-tax Act, 1961,” according to the statement of objects and reasons.
Key Changes Proposed By The Committee
Tax refunds
Removal of the provision that denied income-tax refunds if returns were filed after the due date.
The withdrawn version required taxpayers to file ITRs within the due date to claim a refund (Section 433). The revised Bill ensures refunds can still be claimed even if the ITR is filed late.
Inter-corporate dividends
Restoration of Section 80M deduction (Clause 148) for inter-corporate dividends for companies availing the special tax rate under Section 115BAA.
This provision had been missed in the earlier draft.
Nil TDS certificate
Taxpayers will be allowed to avail of Nil TDS certificates, enabling no tax deduction at source under certain conditions.
Exemption on anonymous donations
Anonymous donations to purely religious trusts will be exempt from tax. The exemption will not apply to trusts that are both religious and engaged in social services such as running hospitals or schools.
Digital-first tax process
The new Bill aims to make the tax process more digital, automated, and faceless, to enhance convenience and minimise the scope for corruption.
Clarification on capital gains tax rumours
Reports last month suggested that the new Bill might change capital gains tax rates. The Income Tax Department denied this in a post on X, stating that the Bill’s objective is language simplification and removal of redundant or obsolete provisions, not altering tax rates.
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More
Read More
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India
The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.
Trump pays tribute to Lou Holtz after legendary football coach’s death
US Senate backs Trump’s Iran operations after House vote
Harry Kane calf injury imperils Bundesliga record chase
Attock Cement’s acquisition approved | The Express Tribune
What are Iran’s ballistic missile capabilities?
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week ago
Attock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days ago
India Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports1 week agoSri Lanka’s Shanaka says constant criticism has affected players’ mental health
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’